Meng Liying, Wu Guanzhao
Department of Central Laboratory and Mitochondrial Medicine Laboratory, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University Qingdao China
RSC Adv. 2023 Jul 10;13(30):20476-20485. doi: 10.1039/d3ra03313a. eCollection 2023 Jul 7.
Mitochondrial disorders are observed in various human diseases, including rare genetic disorders and complex acquired pathologies. Recent advances in molecular biological techniques have dramatically expanded the understanding of multiple pathomechanisms involving mitochondrial disorders. However, the therapeutic methods for mitochondrial disorders are limited. For this reason, there is increasing interest in identifying safe and effective strategies to mitigate mitochondrial impairments. Small-molecule therapies hold promise for improving mitochondrial performance. This review focuses on the latest advances in developing bioactive compounds for treating mitochondrial disease, aiming to provide a broader perspective of fundamental studies that have been carried out to evaluate the effects of small molecules in regulating mitochondrial function. Novel-designed small molecules ameliorating mitochondrial functions are urgent for further research.
线粒体疾病在各种人类疾病中都有发现，包括罕见的遗传疾病和复杂的后天性疾病。分子生物学技术的最新进展极大地扩展了对涉及线粒体疾病的多种发病机制的理解。然而，线粒体疾病的治疗方法有限。因此，人们越来越关注确定减轻线粒体损伤的安全有效策略。小分子疗法有望改善线粒体功能。这篇综述聚焦于开发用于治疗线粒体疾病的生物活性化合物的最新进展，旨在为评估小分子调节线粒体功能的作用而开展的基础研究提供更广阔的视角。设计新颖的改善线粒体功能的小分子亟待进一步研究。
